Compare Axon Enterprise Inc (AXON) vs Johnson & Johnson (JNJ) Price & Performance

AXON trades at $599.78, up 0.58% on the day, consolidating after a strong uptrend. The stock shows bullish technical signals with support near $616 and resistance at $649. Fundamentally, Q2 2026 revenue grew 35% year-over-year to $904 million, marking the tenth consecutive quarter of growth above 30%, with a net income margin of 6.19%. Analyst consensus is strongly bullish with an $685 price target, though valuation multiples remain elevated.

The outlook is positive given robust revenue growth and AI-driven expansion, but the high P/E of 265 presents a significant risk. Investors face a trade-off between strong operational execution and demanding valuations. Near-term catalysts include Q3 2026 earnings and continued execution on the $15.1B future contracted bookings pipeline.

Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.

Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.